Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The entire NYSE was shut down for 3.5 hours due to a "computer glitch."
You can't go wrong with #2
I trade through USAA and this morning noticed the same thing but it says +.12. I thought computer glitch but after you posted that I am not sure.
GLTS
Hey all! I have been with BMSN for well over a year and rarely post. I am in the military and trade through USAA. I just checked and have my divy shares posted.
GLTA
Solos does not sell hair products. What makes you think some doctor is going to write about how great their products are? Do you think a doctor's office just calls customer service to order a mammoview machine?
I'll take mine with
BOSTON, MA -- (Marketwire) -- 07/13/12 -- Solos Endoscopy, Inc.'s (PINKSHEETS: SNDY) is pleased to announce that the Company has begun marketing its new endoscopic instrument line, SteriTAP?. Solos' SteriTAP? Instruments are designed to be the ultimate sterile "take a part" endoscopic instruments of their kind and will be marketed and sold worldwide by Solos Endoscopy.
Solos' SteriTAP? instruments are also approved to immediately receive the CE Mark, which will allow the product to be marketed in those countries where the CE Mark is required, once Solos Endoscopy receives its proper certifications. The SteriTAP? instruments are now available and are featured on the Company's website, http://www.solosendoscopy.com/steritap.html. The SteriTAP? instruments include Dissectors, General Surgery Instruments, Graspers, Gynecology Instruments, Lymphadenectomy Instruments, Needle Holders, Scissors, and Thorascopy Instruments.
According to Reportlinker, the demand for endoscope services is increasing due to an increase in the aging and chronically ill population worldwide. Advancements in endoscopic technologies and inclusion of various types of lighting sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market. Endoscopy procedures have become highly effective in the diagnosis, treatment, and management of cancer patients. Many now consider endoscopy to have become the gold standard for cancer diagnosis and treatment, as well as for many other medical conditions.
There are other reasons that minimally invasive surgical (MIS) procedures like endoscopy are gaining ground in the overall medical arena. Endoscopic procedures, in general, have a lower cost than their counterparts in traditional surgery. In some cases, the patient only needs light sedation as opposed to full anesthesia. Reduced post surgery monitoring time is required for patients undergoing endoscopic procedures. Finally, there is usually a significantly reduced period the patient has to stay in the hospital along with reduced ancillary costs associated with a post-surgical hospital stay.
The SteriTAP? Instrument line is part of the extensive product line of Solos Endoscopy instruments, which are all featured on the Company's website, http://www.solosendoscopy.com/.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the Pink OTC Markets (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Contact Information:
Amanda Segersten
rsegersten@solosendoscopy.com
Advances in Breast Surgery: Intraductal Papillomectomy
Division of Breast Surgery to offer scarless, endoscopic procedure to detect intraductal papillomas
Patients at NewYork-Presbyterian Hospital/Columbia University Medical Center will soon benefit from yet another in a long string of advances: intraductal diagnosis, and eventually, treatment of breast papillomas. Intraductal papillomas are benign lesions within the milk ducts that account for 40% of cases of pathologic nipple discharge in women aged 20-40.
The development of intraductal approaches to diagnosis and treatment represents one of the most important advances in breast disease treatment in the past decade. Intraductal techniques allow surgeons to perform evaluations through the nipple using very fine micro-endoscopes without surgery and without general anesthesia. This minimally invasive approach has been proven highly successful in the detection of papillomas. Sheldon M. Feldman, MD, Chief, Breast Surgery Section, is considered the most experienced breast endoscopist in the U.S., having researched and used minimally invasive techniques for ten years.
Now, NYP/Columbia is poised to become the only facility in the U.S. to offer scarless endoscopic papillomectomy for diagnosis of pathologic nipple discharge. This unprecedented advance will be made possible in large part by the presence of Fatih Levent Balci, MD, a postdoctoral research scientist who also has extensive expertise in endoscopic ductoscopy. In his native Turkey, Dr. Balci and colleagues determined that the intraductal approach could be successfully used not only for the diagnosis of intraductal lesions, but also to remove single papillomas. In his 2009 paper published in Onkologie, "Scarless Endoscopic Papillomectomy of the Breast," Dr. Balci's team found that the technique had 95% therapeutic efficacy in patients with pathologic nipple discharge due to papillomas. "Using this procedure, we can remove single papillomas in an office with a local anesthetic cream," Dr. Balci says despite its value in treating papillomas, endoscopic papillomectomy is currently restricted to diagnostic purposes in the U.S., as the super-fine micro-endoscope needed for removal of papillomas has not yet received FDA approval in this country. That technology is currently available in Turkey, permitting endoscopic removal of papillomas in patients there. Dr. Balci and Dr. Feldman have submitted applications for approval of the necessary catheter so that NYP/Columbia can begin using intraductal ductoscopy for both detection and removal of breast papillomas at this hospital. That process is likely to take several months, according to Dr. Balci.
In addition to its role in detecting and removing papillomas, Dr. Balci points to yet another potentially groundbreaking role of intraductal endoscopy: Detection of ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer in the milk ducts. Although studies have yet to confirm his group's early findings, Dr. Balci's team has been able to detect DCIS using intraductal endoscopy during its research in Okmeydani Teaching and Research Hospital, Istanbul, Turkey, from 2004 to 2009. "DCIS does not always appear on conventional imaging such as MRI or mammography, but early results of our study indicate that DCIS can be detected during ductoscopy. The ability to detect breast cancer before our conventional imaging models find it would be an enormously valuable advance." Moreover, Dr. Balci explains it would be possible to easily extract just the isolated duct using ductoscopy and microductectomy. "Extracting just the isolated duct should give women the best cosmetic result, with no deformity of the breast," he says.
Dr. Feldman concludes, "By assembling a robust team with expertise in mammary ductoscopy and ductscopic minimally invasive procedures, we are well poised to advance diagnosis and treatment of breast cancer."
To learn more, visit: breastmd.org
http://www.columbiasurgery.org/news/healthpoints/2012_fall/p3.html
Here is the link for the various endoscopic companies. Solos is certainly in good company here.
http://endoscopes.com
GLTL
No problem. These are just a few more examples that I have found while my car is getting an oil change.
My point for posting this is to show that one, this is still an up and coming early detection treatment which will continue to improve as it becomes more main stream. Two, these articles come from St Louis, MO, Cincinnati, OH, and Texas, this is just a few. There are far more out there and this is only the beginning.
All can take it for what it's worth.
GLTA
Breast Cancer Screening/Prevention
Fiberoptic Ductoscopy: Fiberoptic ductoscopy (FDS) is a new technique that builds on ductal lavage and allows physicians to directly visualize the inside of a milk duct. During this procedure, a small, flexible tube containing a video camera is inserted into the milk duct, creating a live picture of the inside lining of the duct. This allows the physician to visualize the lining of the milk duct and identify any abnormalities. As in ductal lavage, a salt-water stream washes cells out of the duct for examination under a microscope.
In clinical trials, fiberoptic ductoscopy has proven effective in identifying abnormal cellular masses. This procedure is still being evaluated in clinical trials, but could potentially serve as an additional screening procedure, especially for women who are experiencing nipple discharge.
For full article:
http://www.texasoncology.com/types-of-cancer/breast-cancer/breast-cancer-screeningprevention/
Breast Imaging in Nipple Discharge Evaluation
Updated: Sep 4, 2013
Recent studies:
According to Kapenhas-Valdes and coworkers, mammary ductoscopy is useful in evaluating patients who have nipple discharge, revealing papilloma in 45% of patients (42 of 93), cancer in 6.5% (6 of 93), and atypia in 6.5% (6 of 93). They noted that in their study, mammary ductoscopy was helpful for accurate visualization, analysis, and excision of intraductal abnormalities, especially deeper intraductal abnormalities.[1, 2]
Vaughan et al, in a study of 89 patients with pathologic nipple discharge, found that the combination of visualization by ductoscopy and pathologic analysis of washings provided the highest predictive value for the diagnosis of papilloma. More than 90% of patients with pathologic nipple discharge were found to have a lesion on pathologic examination when this technique was used for directed duct excision. Cellular yields were excellent, with specimens yielding more than 5,000 epithelial cells/hpf and with evaluable ductal cells in 82% of specimens.[3]
Tokuda et al found that MRI (1.5-T system) provided clinically useful data in 47 patients with suspicious nipple discharge. The MRI images were evaluated for a signal of abnormal discharge, related abnormal enhancement according to the breast imaging-reporting and data system MRI descriptors, and the presence of clustered ring enhancement; they were compared with the histopathologic diagnoses established in 39 lesions. The most common finding was non-masslike enhancement, and 17 malignant lesions and 22 benign lesions were detected. The most frequent findings in the malignant lesions were segmental, heterogeneous, and plateau patterns. Clustered ring enhancement was found in 60% of the enhanced malignant lesions.[4]
For full article:
http://emedicine.medscape.com/article/347305-author
Comparison of Ductoscopy, Galactography, and Imaging Modalities for the Evaluation of Intraductal Lesions: A Critical Review
Background: Today, in cases of nipple discharge of unclear origin, the abundance of diagnostic procedures - a ‚diagnostic dilemma' - becomes apparent, because unequivocal indications and a current, standardized examination sequence are presently not available. The diagnostic workup of patients with nipple discharge usually includes the clinical history, physical examination, mammography, ultrasonography, galactography, and nipple discharge cytology, but not ductoscopy. Methods: In this review we analyze and discuss the possible role of ductoscopy in evaluating intraductal pathologies and its combined use with diagnostic imaging modalities. For this purpose, we reviewed and compared the results of the radiological, pathological, and surgical studies independently. Conclusions: Currently, there is no solitary accurate modality to reach our definitive purpose. Being aware of the capability of each diagnostic modality may take us closer to our target. Therefore, adjunct and appropriate use of multiple imaging modalities and ductoscopy is necessary to evaluate patients with nipple discharge.
© 2013 S. Karger GmbH, Freiburg
For full article:
http://www.karger.com/Article/FullText/355833
Mercy Health Physician and Breast Surgeon Hilary Shapiro-Wright Brings Ductoscopy Skills and Experience to Cincinnati for Patients with Pathologic Discharge
(CINCINNATI; May 1, 2013) – Nipple discharge is an alarming physical phenomenon to anyone who experiences it. Usually it’s the result of something benign but in the cases where it’s not, Mercy Health, which provides quality care with compassion in your neighborhood through its network of care, offers minimally invasive ductoscopy as a treatment option for patients who need it.
“Nipple discharge is among the most common breast problems,” says Mercy Health Physician and breast surgeon Hilary Shapiro-Wright, DO, a fellowship-trained and experienced ductoscopy expert. “Our first step is to determine if the discharge is pathologic. Pathologic discharge warrants further investigation.”
Pathologic discharge is typically unilateral (from one side), spontaneous, bloody and/or associated with a mass. This type of discharge tends to stem from one duct, most often as the result of an intraductal papilloma, a small, noncancerous tumor that grows in a milk duct of the breast.
Ductoscopy, which Dr. Shapiro-Wright describes as a “colonoscopy of the breast,” enables her to look inside the duct that’s creating the discharge and isolate the duct involved. Dr. Shapiro-Wright can then remove the lesion right then and there. She uses a tiny, four-millimeter fiber optic camera for the procedure, which lasts up to 90 minutes and takes place in an operating room with patients under sedation and local anesthetic.
“With ductoscopy, I can see cancer even before it’s a palpable mass and remove it and the involved tissue area,” says Shapiro-Wright.
Dr. Shapiro-Wright notes that ductoscopy has numerous benefits for patients.
“Unlike other methods for treating pathologic nipple discharge, ductoscopy is very precise and requires only a small incision, minimizing the tissue that a surgeon needs to remove. This decreases the risk for nipple loss and for complications. It is less disruptive to the duct infrastructure, looks better cosmetically and women of childbearing age can still breast feed after the procedure,” she says.
Dr. Shapiro-Wright sees patients at Mercy Health – Kenwood Breast Surgery, located at 4700 East Galbraith Road, Suite 105, Cincinnati 45236. To learn more about Dr. Shapiro-Wright or to schedule an appointment, please call 513-924-8535 or visit www.e-mercy.com.
Mammary ductoscopy is still a very young technology that has not yet hit the mainstream in the US. There have been sales within the US but it has mainly been to University Hospitals and government medical facilities. All of these have documented the products as being successful. This has all been posted in the board before.
IMO the only reason this has not taken off in the US is because privatized medicine is still a little reluctant to change.
This is why Solos has put so much focus on Europe and Canada. Both have socialized medicine who are always looking for a new cost effect medical treatment technology. You mentioned earlier how the EU had financial problems in the medical field. Mammary ductoscopy are non-abrasive procedures that are far less expensive then current breast cancer prevention and treatment procedures. They also provide a far better success rate in early detection, treatment, and survival.
I am merely summarizing and paraphrasing the research I have done. Go and look for yourself, it is out there.
Why would any company want to acquire, merge, or conduct a joint venture with SNDY?
Easy!
CE Mark and FDA approved products in an new and evolving technology.
Do your DD on this topic and you will see that Solos is a pioneer in the Mammary ductoscopy field. One of the very few with CE Mark and FDA approved products.
Do your DD on the technology and the evolving demand in this medical technology field.
Yes, I agree. That is already being produced in Europe and was just waiting the CE Mark. Thanks for reminding me.
GL to you too.
Solos products have NOT failed to sell in the US. The Mammary ductoscopy is still a new evolving medical procedure. I suggest doing a little more DD on the topic.
This procedure is less evasive and less expensive than current procedures. Again, do a little more DD on the topic.
Solos has become an industry pioneer with regard to the Mammary ductoscopy medical procedure and the Mammowview, which will continue to evolve, sets the standard in this industry. Again, do a little more DD in the topic.
As we focus on Europe we always forget about Canada. IMO Canada will be where Solos makes their money in the short term. Do some DD on how desperate the Canadians are with regard to getting ahead of the breast cancer epidemic.
Everyone needs I do a little more DD on the science and the potential of the Mammary ductoscopy procedure and how Solos will revolutionize it.
GL with what ever direction everyone goes.
I agree, it is 100% laughable.
Although I do believe knowing a companies history is important, solos makes new history everyday. This company has made great strides to toward it's operational goals and to say otherwise is nonsense.
I have invested in this company because I believe in it's products, it's business plan, and it's company leadership.
All I see are FDA and CE Mark approved products. A tremendous amount of growth potential.
GLTA who take the time to conduct applicable DD focusing on the growth of the company regardless of the constant barrage of distorted facts.
Solos has done everything they have said they would do from day one. There may have been delays and setbacks but that is business.
IMO the CEO has been very accommodating to investors and it seems every time a person gets close to the company they stop posting. I suspect that is at the request of the company as to not release any critical info.
All most all of Solos products are FDA and CE Mark approved. All future products developed will have this same certification. That alone is something any larger company would be interested in. The SteriTap is just an example. I am sure Solos has others in development as well.
Certification says it all and Solos is certified in two continents. Many of their competitors who are trading higher than SNDY can not say the same.
Use your head and think about the big picture.
Too easy!
GLTA true longs!
You are absolutely correct.
Everything Solos has done has been to move this company forward successfully. This is a great company with a bright future.
FDA and CE Mark approved products says I all. These products will continue to evolve and get better.
A bright future indeed.
GLTA
Has anyone else come across this web site? Solos seems to be in some very good company here.
http://endoscopes.com/
Not bad for a "Stinky Pinky."
GLTA True Longs!
I absolutely agree.
The Solos management has been building toward it.
GLTA
Regarding the paper in question. The writer is not just a "student." The paper is a Masters level thesis from one of the top business schools in the world.
Regardless it is just a written hypothesis, take it or leave it.
All case studies are written by evaluating a segment of the entire topic subject. The topic in this case has to do with medical devices and the CE Mark.
This paper is not at all "misleading" nor is it biased, it is a Masters level thesis.
Again, take it or leave it.
On another note; awesome post penny!
GLTA true longs!
I did read it and my take away from it was that it provides a case study of a potential course of action. A pretty good one at that.
Again, "the point" has to do with companies that have CE Mark and FDA approved products. The specific companies being evaluated are irrelevant.
Perhaps taking a harder look at the breast cancer epidemic in the EU and Canada is a better gage of Solos's growth in those markets. Tie this in with the differences in the US and EU/ Canadian healthcare. I bet Solos has been looking hard at this and so has a number of larger companies.
Solos's value just went up pretty high with these accreditations. That is a no brainer.
Yeah you already said that. The paper is relevant no matter how you look at it.
The point of the paper is to look at the EU Market (regardless of the products) and explains why companies with both CE Mark and FDA approved products are acquired by larger companies.
This paper, along with prior SNDY PRs and Shareholder letters indicating that this is a desired goal of the Solos management, gives us (the shareholder) a good indication of what may come in the days and weeks ahead.
Like everything this is a hypotheses. A pretty good hypotheses in my unbiased opinion.
Either way you look at it the CE Mark is a huge positive for Solos and us (the shareholders.)
Nice green days ahead for sure.
GLTA true longs!
Exactly! I understand Boost Marketing has been used by less than reputable companies to pump their pps but I have not seen any indication that this is what SNDY has been using them for. At all.
The entire Boost Marketing connection has been falsely used as something it's not.
All in my opinion of course but I do not see it.
I also agree.
Blueskies, you are absolutely right. This comment clears up the SEC Global lock threat completely.
"Since that time,Solos Endoscopy’s legal counsel provided DTC a legal opinion, on December 19, 2013,to confirm that each of the Subject Securities, including the Notice Securities, were, at the date of deposit at DTC, eligible under the Rules and Procedures of DTC to be deposited for the Services."
We never knew why the SEC issued the Global Lock threat and this part of the letter (to confirm that each of the Subject Securities, including the Notice Securities, were, at the date of deposit at DTC, eligible under the Rules and Procedures of DTC) tells us what the SEC's questions were and that they have since been answered.
The fact that the suspense date has come and gone is also and indicator that this is a non-concern.
Any speculation otherwise is just that, speculation, that has no merit. It is a dead subject.
Thank you for reposting and explaining this.
GLTA true longs.
Than ultimately we agree.
Penny stocks have a bad reputation because of all of the fraud companies that only go public to ruse investors by pumping it up and diluting down to nothing. Stealing all investors money. We know they are out there. That is why we have to rely on our own DD to figure out which companies are real and which ones are not.
As far as identifying Penny stocks that were successful, that is relative. Success is relative and I guess it depends of each investors personal investing goals.
For me I see SNDY as a company that has proven products that are about to enter the global market. The certifications alone holds a heavy value. Therefore dilution can be positive when used effectively to finance company needs.
If I sounded rash on my last post I apologize. I may have misunderstood the intention of your first comment.
GL
I saw this on another board. Thought it was worth sharing.
GLTA!
Learn before you speak.
What is Dilution?
Is it good, or bad ?
Dilution is when the company moves shares from the AS (authorized shares) to the OS (outstanding shares) or tradeable inventory, for cash investments in the company.
This means there are more shares at the same market price and reduces the size of the EPS. It doesn't reduce the price or value of the stock. But many pennylanders think it does.
Dilution doesn't change price, it changes EPS. Creating loss in company value, not stock value.
Hardly 1 in a 1000 OTC companies have an EPS to effect. So, dilution can't effect their company value in the first place. Whats the value of no earnings, thus no EPS.
But, the value of more cash to a startup is huge! Cash gives them the ability to attempt to grow. Without the cash it can't. So logic says, the retail herd should be happy about dilution.
After all, they want the comapny to grow don't they.
On the OTC, "dilution" is the best news one can hear !
Not only does it give the company a chance at growth, it doesn't effect their EPS value one bit. They have no EPS to effect. Plus, every time VCs get there hands on large amounts of shares, they buy a run, and we can trade for profits !
So, "dilution" is a win for the company, a win for the Venture capital firm, and a win for the educated pennyland trader, on the OTC.
Like I said, it's all perception and mine is brighter. We'll see.
Good luck either way
I have heard all of this before. Got it. None of it changes my unbiased point of view for the future of this company. Take it or leave it, I do not care.
IMO we will jump back over a penny pretty fast once CE Mark certification news hits. I believe that there are a lot of people sitting on the sideline waiting for that news to jump in.
To me the question we be what next. We keep talking about the Mammoview but we also have the SteriTAP. The news of the SteriTAP but us over a cent last time and the SteriTAP is already being produced in the EU. We just need CE to sell. Not to mention that CE will cover all Solos products.
Regardless I want to see what Solos will do after CE Mark is attained. If there is a delay in additional news we may slowly slip back down in share price. I have no idea how far.
If CE Mark is complemented by news of merger, takeover, JV, or whatever, then skies the limit.
IMO Solos leadership has been working hard to wrap up all of their loose ends. They have been working hard for a long time to reach this point. I am anxious to see the results in the days ahead.
GLTA
This is a great collection of some of the less than desirable business activities Solos Endoscopy has been a part of over the years. Business is hell. Your selection of adjectives really gets your point across. Of course it covers only half the story.
I am invested in Solos's future, not its past. Everything on here can be mitigated, to include the so called pending global lock. It will not happen.
Good luck in wherever your ambition lays.
That is because there is not much else to be said about them. Does not mean they have stopped using them.
Solos products are for preventive medicine. Detecting Breast cancer in it earliest stages. Most US DRs are still comfortable with using the standard mammogram as prevention and are not fully convinced in the Mammoview. I hate to say it but with later detection comes more treatment. Privatized medicine is a business.
In the EU they put more emphasis in preventive medicine because it is more cost effective in the long run.
In my opinion Solos products have to succeed in the EU before it can in the US.
Not a real company? Try talking to the National Cancer Institute (NCI) or the U.S. National Institute of Health (NIOH) about their products.
Try contacting the FDA. I do not believe they approve products that don't exist.
Try doing some real DD and not relying on this site as your only source of information.
Also Try running their Dun & Bradstreet report to find out their credit rating. Last month they were listed as a "moderate credit risk." This month they are listed as "Low Credit Risk."
Seems to me like management is working hard to cleanup their books. I could only wonder why.
A company with FDA and CE Mark approved products, minimal debt, and excellent credit rating. A large amount of stock shares being bought before hitting the market. I feel comfortable with the way things are going.
GLTA true longs
I would never marginalize anything. Everything I post is based on my owe research and interpretation. As I have stated numerous times, I base my conclusions and determinations on ALL of the information provided.
I learned this ability from three places. The US Army Military Intelligence School, the Office of Directorate of National Intelligence, and the FBI Academy. Plus over 20 years of experience.
I know how to draw a conclusion based on facts.
GLTY!
Overall we have no idea the intent of the DTC as the memo is vague. You and others are trying to imply that a global lock is going to happen. Providing everyone the worst case scenario.
If the DTC had enough evidence against SNDY they would have put a global lock on them immediately. Because they didn't tells me that they had a few questions that needed answering and nothing more.
This is all a part of the new DTC notification procedures. It is like getting a letter in the mail telling you that your credit will be harmed if you don't pay your bill. Pay the bill and no harm done.
This is not the doom and gloom you may think or imply.